Recently, there is increasing interest in the role of peripheral mineralocorticoid receptors (MR) to modulate pain, but their localization in neurons and glia of the periphery and their distinct involvement in pain control remains elusive. In naive Wistar rats our double immunofluorescence confocal microscopy of the spinal cord, dorsal root ganglia, sciatic nerve and innervated skin revealed that MR predominantly colocalized with calcitonin-gene-related peptide (CGRP)-and trkA-immunoreactive (IR) nociceptive neurons and only marginally with myelinated trkB-IR mechanoreceptive and trkC-IR proprioreceptive neurons underscoring a pivotal role for MR in the modulation of pain. MR could not be detected in Schwann cells, satellite cells, and astrocytes and only scarcely in spinal microglia cells excluding a relevant functional role of glia-derived MR at least in naïve rats. Intrathecal (i.t.) and intraplantar (i.pl.) application of increasing doses of the MR selective agonist aldosterone acutely increased nociceptive behavior which was reversible by a MR selective antagonist and most likely due to non-genomic effects. This was further substantiated by the first identification of membrane bound MR specific binding sites in sensory neurons of dorsal root ganglia and spinal cord. Therefore, a crucial role of MR on nociceptive neurons but not on glia cells and their impact on nociceptive behavior most likely due to immediate non-genomic effects has to be considered under normal but more so under pathological conditions in future studies.
Introduction
Mineralocorticoid receptors and their endogenous ligand aldosterone are best known for their control of the water and electrolyte balance in the kidney and their involvement in volume and blood pressure regulation (Te Riet et al., 2015) . In addition, aldosterone has also been reported to promote inflammation, fibrosis, and remodeling in the heart and vasculature (Ferrario and Schiffrin, 2015; Young and Rickard, 2012) . Interestingly in older studies, a combination of aldosterone and its antagonist spironolactone revealed an immunosuppressive effect in allogenic skin grafts (Baethmann et al., 1971) , multiple sclerosis (Mertin et al., 1972) , and progressive systemic sclerosis (Altmeyer et al., 1985) . All these effects occur by the classical pathway at which aldosterone easily diffuses the cellular membrane, binds to its cytoplasmic MR and e upon dissociation of chaperons and formation of MR dimers -is translocated to the nucleus resulting in the enhanced or inhibited expression of several genes (Te Riet et al., 2015) . The effects of aldosterone via intracellular MR are usually characterized by a 45-min up to several hours lag period (Funder, 2005) . In contrast to these genomic effects more rapid non-genomic effects have also been demonstrated particularly in neurons of the nervous system (Groeneweg et al., 2012) . Corticosteroids for example rapidly alter neuronal excitability throughout the brain and as a consequence regulate adaptive behavior and memory (Groeneweg et al., 2012) .
Recently, increasing interest has focused on the role of MR in different conditions of pain. In a model of chronic compression of the L5 lumbar dorsal root ganglion the twice daily intrathecal injection of the MR antagonist spironolactone over three days resulted in a significant reduction of mechanical allodynia (Gu et al., 2011; Sun et al., 2012) . In another model of zymosan-induced local inflammation of the L5 dorsal root ganglion, the combined local application of zymosan with the MR antagonist eplerenone reduced for an extended period of time the mechanical hypersensitivity (Dong et al., 2012) . In the same study MR were shown in dorsal root ganglia to colocalize with the pan-neuronal cell marker NeuN and eplerenone treatment apparently decreased the number of activated satellite glia cells. Since these effects occurred with some delay and lasted several days, they were most likely due to genomic effects of the MR. Up to now, evidence for the exact subpopulations of DRG neurons and glia cells that express MR and for putative short lasting non-genomic effects resulting from neuronal membrane bound MR is lacking.
Therefore, we systematically investigated in naive rats i) the presence of MR specific mRNA and receptor protein in spinal cord, dorsal root ganglia and innervating sciatic nerve compared to kidney; ii) the localization of MR in neurons, astrocytes and microglia of the spinal cord, iii) the localization of MR to myelinated, unmyelinated, nociceptive, mechanoreceptive and proprioceptive neurons in dorsal root ganglia; iv) the characterization of MR-ir nerve terminals in the subepidermal and epidermal layer of the skin; v) the changes in nociceptive behavior following the local i.pl. or i.th. administration of a MR selective agonist with and without antagonist; vi) the evidence for membrane bound MR by saturation binding with the radiolabeled MR selective ligand [ 3 H] aldosterone.
Methods

Reagents
The following drugs were used: aldosterone, canreonate-K (Sigma-Aldrich, St. Louis, MO, USA); doses were calculatedwhere applicable -in terms of the free base. Canreonate-K was dissolved in NaCl 0.9%, aldosterone was dissolved in a vehicle composed of 10% ethanol and 90% normal saline, as described previously (Gravez et al., 2013) . Routes and volumes of drug administration were i.t. 20 mL and i.pl. 100 mL. Intrathecal injections were performed under inhalational anesthesia with the rat in the elevated lumbar position. Intraplantar injections were given under inhalational anesthesia into the subcutaneous tissue of the glabrous skin directly proximal to the callosities of the toes. The drug or its solvent were injected into the intrathecal L3-L4 interspace (spontaneous tail movement being a positive indication for correct i.t. positioning) with a 30-gauge needle connected to a 50 mL syringe. In accordance with previous studies (Myers and Van Meerveld, 2009; Khan and Bakshi, 2009) , separate groups of animals for each dose and injection technique received i.pl. or i.t. administrations of different doses of: aldosterone (i.pl. 25e100 mg or i.t. 4e40 mg) with and without canreonate-K (150e500 mg). Control animals received vehicle treatment. Experiments were performed in a blinded way to the drugs and doses applied.
Animals
Experiments were conducted in male Wistar rats (200e250 g) (breeding facility, Charit e-Universit€ atsmedizin Berlin, Germany) after approval by the local animal care committee and in accordance with the European Directive on the protection of animals used for scientific purposes (2010/63/EU).
Characterization of antibodies
The species, sources, dilutions, and immunogens of the primary antibodies used in this study are summarized in Table 1 .
Tissue preparation
Rats were deeply anesthetized with isoflurane and the subcutaneous paw tissue, sciatic nerve, dorsal root ganglia, spinal cord, and kidney were removed from adult rats for subsequent qRT-PCR and western blot experiments.
RT-PCR
The total RNA was prepared from kidney, DRG and spinal cord of rats with the commercially available Kit Qiazol Lysis Reagent, (Qiagen, Hilden, Germany) according to the manufacturer's protocol. 500 ng total RNA, measured by Nanodrop (Peqlab) was applied for transcription of cDNA using Omniscript RT Kit (Qiagen, Hilden, Germany) as followed: 0.5 mM dNTP, 1 mM Random Primer, 10 units RNase Inhibitor and 4 units Omnisript reverse Transcriptase. Samples were incubated at 42 C for 1 h and cDNA were stored 
Western blot
Kidney, DRG, spinal cord or peripheral (sciatic) nerve from adult rats were solubilized according to Weems et al. (1996) . Western blot analysis was performed as previously described (Ji and Rupp, 1997; Mousa et al., 2010) . Briefly, the samples were homogenized in RIPA-Buffer and the lysate was centrifuged at 16.000 g for 20 min. The protein concentration of the supernatant was measured using a BCA assay (Pierce, Rockford, IL, USA). Subsequently 10e20 mg protein were denatured in SDS sample buffer (5Â loading buffer: 200 mM Tris, pH 6.8, 10% SDS, 20% glycerol, 10% 2-mercaptoethanol and 0.05% bromophenol blue; filled up with RIPA buffer) for 10 min at 80 C. The extracts were separated using 7.5% Mini-PROTEAN TGX Stain-Free Precast Gels (Bio-Rad, Copenhagen, Denmark). After SDS-electrophoresis, the gels were activated using UV light. The activated gel was then electrophoretically transferred to a nitrocellulose membrane using the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories GmbH, München, Germany). After blotting the protein transfer was visualized by taken a UV light exposure image. The membranes were blocked in 3% BSA for 2 h and incubated with rabbit anti-MR (Santa Cruz, 1:2.000, in 3% BSA) overnight at 4 C. This antibody has been proven to be highly specific following MR-transfection and knock-down in different cell lines (O'Hara et al., 2014; Jeong et al., 2009) . After incubation with the secondary antibody (peroxidase-conjugated goat anti-rabbit, 1:40.000, Jackson ImmunoResearch) for 2 h at room temperature, reactive protein bands were digitally visualized using ECL solutions (SuperSignal West Pico, Thermo Scientific) in ChemiDoc MP Imager. Finally, the blots were reprobed with monoclonal mouse anti-beta Actin antibody (1:20.000; Sigma Aldrich) as an internal standard. Experiments were repeated three times.
Immunohistochemistry
Tissue preparation
Adult rats were deeply anesthetized with isoflurane and transcardially perfused with 100 ml warm saline, followed by 300 ml 4% (w/v) paraformaldehyde in 0.16 M phosphate buffer solution (pH 7.4). After perfusion the subcutaneous tissue, sciatic nerve, DRG and spinal cord were removed and fixed in the same fixatives for 90 min, and then cryoprotected overnight at 4 C in PBS containing 10% sucrose. The tissues were then embedded in tissue-Tek compound (OCT, Miles Inc. Elkhart, IN) and frozen. DRG or sciatic nerve sections (8 mm thick) were mounted onto gelatin coated slides but spinal cord and subcutaneous sections (50 mm thick) collected in PBS (floating sections).
Double immunofluorescence staining
Double immunofluorescence staining was processed as described previously (Mousa et al., 2007) . Tissue sections were incubated for 60 min in PBS containing 0.3% Triton X-100, 1% BSA, 10% goat serum (Vector Laboratories, CA, USA) (blocking solution) to prevent nonspecific binding. The sections were then incubated overnight with the following primary antibodies: polyclonal rabbit antibodies against MR (Dr. M. Kawata) (dilution of 1:2000) in combination with a polyclonal guinea pig anti-CGRP (Peninsula Laboratories, 1:1000), anti-NF200 (Sigma, 1:1000), goat polyclonal anti-trkA, anti-trkB or anti-trkC (R&D, 1:500). After incubation with primary antibodies, the tissue sections were washed with PBS and then incubated with Alexa Fluor 594 donkey anti-rabbit antibody (Vector Laboratories) in combination with Alexa Fluor 488 goat anti-guinea pig, anti-mouse or anti-chicken antibody (Invitrogen, Germany). Thereafter, sections were washed with PBS, and the nuclei stained bright blue with 4 0 -6-Diamidino-2-phenylindole (DAPI) (0.1 mg/ml in PBS) (Sigma). Finally, the tissue sections were washed in PBS, mounted on vectashield (Vector Laboratories) and imaged on a confocal laser scanning microscope, LSM510, equipped with an argon laser (458/488/514 nm), a green helium/neon laser (543 nm), and a red helium/neon laser (633 nm; Carl Zeiss, G€ ottingen, Germany). Single optical slice images were taken using Â10 or Â20 Plan-Neofluar air interface or Â40 Plan-Neofluar oil interface objective lens. The brightness and contrast of the final images were adjusted in Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA). To demonstrate specificity of the staining, the following controls were included as described in our previous studies (Mousa et al., 2007 (Mousa et al., , 2010 : omission of either the primary antisera or the secondary antibodies. The method of quantification for DRG staining has been described previously (Mousa et al., 2007) . For counting of the total number of neurons, only those immunostained neurons containing a distinct nucleus were counted using the microscope (40 Â objective). In a similar way, the number of GR/MR-, MR/CGRP-, MR/trkA-, MR/trkB-, R/trkC-, NF200-, GFAP-or OX42-IR neurons was counted and divided by the total number of MR-IR neurons in each DRG section and represented as percentages. Data were obtained from two sections per rat and four to five rats per group.
Von Frey filament testing
Rats were placed in a plastic cage for half an hour to acclimate until cage exploration and major grooming activities ceased. At the bottom of the cage a wire mesh allowed full access to the paws. Mechanical hind paw withdrawal thresholds were assessed by the application of a calibrated series of von Frey filaments of logarithmic incremental stiffness (Stoelting, Wood Dale, IL, USA) as described previously (Dixon, 1980; Chaplan et al., 1994; Mousa et al., 2016) . Von Frey filament testing were firstly performed in all groups before drug application to get baseline values. Then, the nociceptive responses were reassessed at different time-points (0e60 min) following drug administrations to determine drugrelated behaviors. Briefly, the resulting pattern of positive and negative responses were tabulated using the convention, X ¼ withdrawal; 0 ¼ no withdrawal, and the 50% response threshold was interpolated using the formula: 50% g threshold ¼ (10 (xfþkd) )/10,000, where x f ¼ value (in log units) of the final von Frey filament used; k ¼ tabular value for the pattern of positive/ negative responses; and d ¼ mean difference (in log units) between stimuli. After baseline measurements von Frey thresholds were reevaluated at different time intervals before and 0e60 min after i.pl. or i.t. injection of vehicle, the MR agonist aldosterone alone or in combination with MR antagonist canreonate-K. The mechanical paw withdrawal thresholds were defined as the mean of 5e6 animals performed before and after i.pl. or i.t. drug injections.
Radioligand binding assay
The following experiments should identify MR specific binding sites in membrane fractions of spinal cord and DRG prepared according to our previous binding studies (Mousa et al., 2010; Shaqura et al., 2004; Z€ ollner et al., 2003) . Membrane fractions from Wistar rat spinal cord or DRG were prepared by homogenizing them in cold assay buffer (50 mM Tris-HCl, 1 mM EGTA, 5 mM MgCl 2 , pH 7.4) and by centrifuging them at 48,000Âg at 4 C for 20 min. The pellet was resuspended in assay buffer followed by 10 min incubation at 37 C to remove endogenous ligands. The homogenates were centrifuged again at 48,000 g and resuspended in assay buffer. Membranes were aliquoted and stored at À80 C (for details see Z€ ollner et al., 2003 for 2 h at 30 C in a total volume of 0.5 ml of binding buffer (50 mM Tris-HCl, 5 mM EDTA, 5 mM MgCl2, 100 mM NaCl, 0.2% bovine serum albumin). Nonspecific binding was defined as radioactivity remaining bound in the presence of 10 mM unlabelled aldosterone.
At the end of the incubation period, bound and free ligands were separated by rapid filtration over GF/C filters under vacuum using a Brandel cell harvester (Gaithersburg, MD, USA). Filters were washed three times with 4 ml of cold buffer (50 mM Tris-HCl, pH 7.4). Bound radioactivity was determined by liquid scintillation spectrophotometry after overnight extraction of the filters in 3 ml of scintillation fluid. All experiments were performed in duplicate and carried out at least three times. analysis of concentration-effect curves using GraphPad Prism (GraphPad Software Inc., CA, USA).
Statistical analysis
All tests were performed using Sigma Stat 2.03 software (SPSS Inc., Germany). MR mRNA data are expressed as means ± s.e.m. Paw withdrawal thresholds determined by von Frey filament testing were expressed as means ± s.e.m and statistically analyzed by one way or two-way ANOVA and post-hoc by Dunnett's or Tukey test, respectively. For all statistical tests, significance was assumed at P < 0.05.
Results
Identification of spinal cord and DRG mineralocorticoid receptor specific mRNA and protein
Using a highly specific primer pair (Fig. 1A) an expected MR specific 85 bp PCR-product was identified in the kidney of naive rats (Fig. 1B, C) . Similar to the expression in the kidney the same MR specific PCR-product was also detected in the spinal cord and dorsal root ganglia of these naïve rats (Fig. 1C) . This was consistent with the demonstration of a MR specific protein band at 107 kDa not only in the kidney, but also in the spinal cord, dorsal root ganglia, and sciatic nerve (Fig. 1D ).
Localization of spinal MR on central nerve terminals of nociceptive neurons
In the dorsal horn of the spinal cord there was abundant colocalization of MR with CGRP, a marker for nociceptive neurons ( Fig. 2) . This colocalization occurred mainly from incoming sensory neurons in Rexed laminae I and II of the grey matter of the spinal cord, whereas few scattered neuronal cells could also be identified in Rexed laminae III and IV (Fig. 2) . Interestingly, MR did not colocalize with GFAP, a marker for astrocytes, and only very rarely with OX-42, a marker for microglia, within the spinal cord of naïve rats indicating its main neuronal localization (Fig. 2) .
Colocalization of MR primarily with CGRP and trkA in nociceptive DRG neurons
Double immunofluorescence confocal microscopy showed abundant colocalization of MR with CGRP (74.9 ± 9.7%) (Fig. 3 , upper panels) and trkA (55.6 ± 7.3%) (Fig. 4, upper panels) ; however, there was less colocalization with NF200 (20.8 ± 3.2%) (Fig. 3 , lower panels), trkB (27.7 ± 4.0%) (Fig. 4 , middle panels) and trkC (15.1± 8.6%) (Fig. 4, lower panels) indicating that the MR is predominantly expressed in nociceptive C-and Ad-neurons, but much less in mechanoreceptive and proprioceptive neurons (Matsumoto et al., 2012) . Approximately 80% of these neurons do not show colocalization with NF200 (Fig. 3, lower panels) indicating that the majority are unmyelinated nerve fibres.
Localization of skin MR on peripheral nerve terminals of nociceptive neurons
Consistently, MR also colocalized to a high degree with the sensory neuron marker CGRP both in peripheral nerve fibers of the sciatic nerve (Fig. 5, upper panels) and in branching nerve terminals within the subepidermal and epidermal layer (Fig. 5 , middle panels), although there were some CGRP-immunoreactive nerve fibers without MR. In addition, MR colocalised to a high degree with the sensory neuron marker trkA in branching nerve terminals of the skin (Fig. 5, lower panels) . These nerve terminals extend as numerous free nerve endings from the subepidermal into the epidermal layer (Fig. 5, lower panels) . Importantly, the MR were not identified over the entire course of the peripheral nerve fibres in accompanying Schwann cells.
Functional role of spinal cord and DRG mineralocorticoid receptors in nociceptive behavior
To assess the functional relevance of the presence of the MR exclusively on nociceptive fibres we performed von Frey filament testing following the local i.pl. or i.th. administration of increasing doses of the MR selective agonist aldosterone. The results show a significant dose-dependent decrease in mechanical thresholds of up to almost 50% following either the i.pl. or i.th. application of aldosterone (Fig. 6A, B) . Co-administration of aldosterone with the MR selective antagonist canreoante K significantly reversed the decrease in mechanical thresholds following both treatments (Fig. 6C, D) . Whereas nociceptive effects of i.th. aldosterone administration were observed on both sides, nociceptive effects of i.pl. aldosterone were seen only ipsi-but not contralateral to the injection side indicating a local peripheral effect (data not shown). (Fig. 7A ) and spinal cord neurons ( Fig. 7B) with B max values of 35.9 ± 5.5 fmol/mg protein and 51.8 ± 6.2 fmol/mg protein and K d values of 24.3 ± 7.3 nM and 11.6 ± 3.4 nM, respectively. In line with these findings and with the antibody specifications (Table 1) , MR-immunoreactivity in DRG neurons of naïve rats was not identified in the nuclear but in the cytosol/plasma membrane compartment (Fig. 7C ).
Evidence for membrane bound MR
Discussion
This study systematically examined the exact anatomical localization of MR within the spinal cord and peripheral nervous system of naïve rats. In contrast to previous reports that used different models of persistent pain (Dong et al., 2012; Sun et al., 2012 ), our results demonstrate that MR are expressed mainly in nociceptive neurons and very rarely in glia cells. In the spinal cord, MR colocalize predominantly with incoming presynaptic CGRP-IR nerve terminals in Rexed laminae I and II. Only few scattered neuronal cell bodies in Rexed laminae III and IV were also positive. In addition, in peripheral nerve fibers of the sciatic nerve and peripheral nerve endings of the skin MR were restricted predominantly to nociceptive neurons such as unmyelinated C-fibers and Ad-fibers and colocalized only marginally with myelinated mechanoreceptive or proprioceptive neurons (Matsumoto et al., 2012) . In Schwann cells, satellite cells, and astrocytes MR could not be identified under normal conditions, though a scant few were found in microglia of the spinal cord. The activation of either spinal or peripheral MR on these nociceptive neurons by local agonist application resulted in a dose-dependent reduction in mechanical thresholds of naïve rats. The use of an MR antagonist demonstrated receptor specificity. These rapid effects in nociceptive behavior together with the presence of neuronal MR specific membrane binding sites in DRG and spinal cord suggest a potential rapid non-genomic mechanism of nociceptive modulation through MR on the plasma membrane of nociceptive neurons.
In recent publications that used different models of persistent pain, MR have been reported to exist in all peripheral neurons (Dong et al., 2012) as well as in glia cells (Sun et al., 2012) . However, peripheral neurons were not further distinguished into subpopulations of peripheral neurons and there is no direct proof of MR in glia cells. Evidence for MR on neurons has been known for a long time: earlier binding studies already suggested two different corticoid receptors within the central nervous system (McEwen et al., 1986) and found evidence for type I (i.e. mineralocorticoid receptor) and type II corticosteroid receptor gene expression (Reul et al., 1989) . Soon thereafter, type I corticoid receptor (MR)-like immunoreactivity was first reported in the spinal cord (Ahima et al., 1991) . However, no data are available on the exact anatomical localization of MR with regards to specific subpopulations of nerve fibers that innervate the periphery. In using a new highly specific polyclonal rabbit antibody against the rat MR that does not cross-react with the glucocorticoid receptor (Ito et al., 2000) we were able to demonstrate MR immunoreactivity in neuronal cell bodies of dorsal root ganglia as well as their peripheral (within skin) and central (within spinal cord) nerve terminals. More importantly, MR immunoreactive neurons strongly colocalized with CGRP, a marker for nociceptive C-and Ad-nerve fibers. Consistently, the majority of MR immunoreactive neurons also colocalized with trkA (Matsumoto et al., 2012) . In longitudinal sections of the innervating sciatic nerve and in sections of arborizing nerve endings at the dermal-epidermal junction of the skin the majority of MR immunoreactive axons colocalized with CGRP which clearly indicates a pivotal role these receptors play in the modulation of nociception. Indeed in our own behavioral experiments with naïve animals, we could demonstrate for the first time an immediate and almost 50% decrease in mechanical thresholds, i.e. increased sensitivity to mechanical stimuli, ipsi-but not contralateral to the i.pl. administration of aldosterone. This peripheral effect occurred within 10 min, persisted for 40 min and was receptor specific as a simultaneous local injection of a MR selective antagonist reversed this effect. The same effect was observed at central nerve terminals of the peripheral sensory neurons when aldosterone with or without its respective antagonist was given intrathecally. Consistent with such a pronociceptive effect, previous studies have shown that the MR selective agonist aldosterone dose-dependently increased the number of action potentials evoked by suprathreshold current injection in acutely dissociated DRG neurons of naïve rats (Ye et al., 2014; Dong et al., 2012) . Interestingly, other studies have described antinociceptive effects of a MR antagonist under different pathological conditions such as low back pain (Ye et al., 2014; Dong et al., 2012; Sun et al., 2012; Gu et al., 2011) and diabetic neuropathy (Dong and He, 2013) . Thus in line with these findings of antinociceptive effects by a MR antagonist, we demonstrate that the application of a MR selective agonist induces nociception under non-pathological conditions.
In addition to neuronal MR, it is discussed whether MR on glia cells modulate nociception (Dong et al., 2012) . However, whereas MR immunoreactive glia cells in the hippocampus (Hwang et al., Fig. 4 . Confocal microscopy of MR (red fluorescence) and trkA, trkB or trkC (all green fluorescence) double immunofluorescence in DRG of naïve rats. Note that the population of DRG neurons coexpressing MR with trkA (55.6 ± 7.3%) was much higher than that coexpressing trkB (27.7 ± 4.0%) or trkC (15.1± 8.6%). All data are shown as means ± SEM.
Bar ¼ 20 mm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 2006; Garcia et al., 2004; Bohn et al., 1991) and retina (Golestaneh et al., 2001 ) have been convincingly demonstrated, there is no direct immunohistochemical evidence of MR in glia cells of the spinal cord or peripheral nerve. Several studies reported the presence of MR in cell cultures of microglia (Girard et al., 2010; Sierra et al., 2008; Tanaka et al., 1997) , but the evidence was mainly gained indirectly through MR-mediated effects. Here in naïve rats we could identify a remote colocalization of MR with the microglial marker OX-42 (Fig. 2) and found no presence of MR in astrocytes, satellite cells or Schwann cells (Fig. 2) . This might be different under pathological conditions such as nerve injury when expression of MR in glia cells might be up-regulated (Dong et al., 2012 ), yet direct evidence is still missing.
The observation in our study that acute nociceptive effects occur within a few minutes after local MR agonist application strongly questions a genomic provenance, particularly since MR at the peripheral nerve terminal need to travel retrogradely the entire length of the sciatic nerve in order to reach the cell nucleus and alter gene expression. Instead, recent evidence repeatedly shows that neuronal MR agonists may also elicit their effects through nongenomic ways (Chatterjee and Sikdar, 2014; Groeneweg et al., 2012) . These non-genomic pathways can be elicited either by directly interfering with intracellular signaling pathways or by interfering with membrane bound structures such as ion channels and G-protein coupled receptors (Chatterjee and Sikdar, 2014; Groeneweg et al., 2012) . Indeed, we further substantiated the evidence for a putative non-genomic pathway in our binding experiments. These demonstrated saturation binding with increasing concentrations of the radiolabeled ligand [ 3 H]aldosterone in the pure membrane fraction of DRG neurons indicating MR specific binding sites. Consistently, our immunofluorescence confocal microscopy showed that MR were not identified in the nuclear but in the cytosol/plasma membrane compartment of DRG neurons. Moreover, we identified MR binding sites in the spinal dorsal horn which might reflect both MR receptors on central endings of primary afferent nociceptors and MR receptors on central neurons. In agreement with our findings, convincing evidence for membrane bound MR is also provided by electron microscopy studies in presynaptic terminals and postsynaptic densities of synaptic areas of the brain (Prager et al., 2010; Johnson et al., 2005) . In contrast to genomic MR, membrane bound MR elicit their effects within seconds-to-minutes and have been shown to increase synaptic and neuronal excitability (Prager and Johnson, 2009 ). In line with this, Dong et al. have shown in dorsal root ganglion neurons of naïve rats that the MR agonist aldosterone dose-dependently increased the number of action potentials evoked by suprathreshold current injection (Dong et al., 2012) .
Conclusions
Taken together, MR predominantly colocalized with peripheral nociceptive neurons and only marginally with myelinated mechanoreceptive and proprioreceptive neurons underscoring their pivotal role in the modulation of nociception. MR were not detected in most of the glia cells e only scarcely in spinal microglia e indicating no relevant functional role of glia-derived MR at least in naïve rats. However, this might change under pathological conditions that are known to elicit glia activation, e.g. neuropathic pain (Ji et al., 2013) . For the first time we can show immediate effects upon activation of MR on peripheral nociceptive neurons that are most likely due to non-genomic mechanisms. This is further substantiated by the identification of membrane bound MR specific binding sites in neurons of dorsal root ganglia and spinal cord. Therefore, the crucial role of MR on nociceptive neurons and their impact on nociceptive behavior most likely due to immediate nongenomic effects has to be considered under normal but more so under pathological conditions in future studies.
